The New England journal of medicine, 2021-12, Vol.385 (25), p.2348-2360
- Falsey, Ann R
- Sobieszczyk, Magdalena E
- Hirsch, Ian
- Sproule, Stephanie
- Robb, Merlin L
- Corey, Lawrence
- Neuzil, Kathleen M
- Hahn, William
- Hunt, Julie
- Mulligan, Mark J
- McEvoy, Charlene
- DeJesus, Edwin
- Hassman, Michael
- Little, Susan J
- Pahud, Barbara A
- Durbin, Anna
- Pickrell, Paul
- Daar, Eric S
- Bush, Larry
- Solis, Joel
- Carr, Quito Osuna
- Oyedele, Temitope
- Buchbinder, Susan
- Cowden, Jessica
- Vargas, Sergio L
- Guerreros Benavides, Alfredo
- Call, Robert
- Keefer, Michael C
- Kirkpatrick, Beth D
- Pullman, John
- Tong, Tina
- Brewinski Isaacs, Margaret
- Benkeser, David
- Janes, Holly E
- Nason, Martha C
- Green, Justin A
- Kelly, Elizabeth J
- Maaske, Jill
- Mueller, Nancy
- Shoemaker, Kathryn
- Takas, Therese
- Marshall, Richard P
- Pangalos, Menelas N
- Villafana, Tonya
- Gonzalez-Lopez, Antonio
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Falsey, Ann R
- Sobieszczyk, Magdalena E
- Hirsch, Ian
- Sproule, Stephanie
- Robb, Merlin L
- Corey, Lawrence
- Neuzil, Kathleen M
- Hahn, William
- Hunt, Julie
- Mulligan, Mark J
- McEvoy, Charlene
- DeJesus, Edwin
- Hassman, Michael
- Little, Susan J
- Pahud, Barbara A
- Durbin, Anna
- Pickrell, Paul
- Daar, Eric S
- Bush, Larry
- Solis, Joel
- Carr, Quito Osuna
- Oyedele, Temitope
- Buchbinder, Susan
- Cowden, Jessica
- Vargas, Sergio L
- Guerreros Benavides, Alfredo
- Call, Robert
- Keefer, Michael C
- Kirkpatrick, Beth D
- Pullman, John
- Tong, Tina
- Brewinski Isaacs, Margaret
- Benkeser, David
- Janes, Holly E
- Nason, Martha C
- Green, Justin A
- Kelly, Elizabeth J
- Maaske, Jill
- Mueller, Nancy
- Shoemaker, Kathryn
- Takas, Therese
- Marshall, Richard P
- Pangalos, Menelas N
- Villafana, Tonya
- Gonzalez-Lopez, Antonio
- Titel
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
- Ist Teil von
- The New England journal of medicine, 2021-12, Vol.385 (25), p.2348-2360
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a randomized, double-blind, placebo-controlled phase 3 trial of the ChAdOx1 nCoV-19 vaccine in over 32,000 participants from the United States, Chile, and Peru, the incidence of serious adverse effects was low (including no cases of vaccine-induced immune thrombotic thrombocytopenia) and the vaccine efficacy was 74%. Efficacy was documented in a range of demographic subgroups.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2105290Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8522798
- Format
- –
- Schlagworte
- Adolescent, Adult, Adverse events, Age, Aged, Aged, 80 and over, Antibodies, Antibodies, Neutralizing - blood, Antibodies, Viral - blood, ChAdOx1 nCoV-19 - adverse effects, Chile - epidemiology, Clinical trials, Collaboration, Coronavirus, Coronaviruses, COVID-19 - epidemiology, COVID-19 - prevention & control, COVID-19 vaccines, Double-Blind Method, Female, Humans, Illnesses, Immunogenicity, Immunogenicity, Vaccine, Infections, Infectious Disease, Male, Middle Aged, Nucleocapsids, Original, Peru - epidemiology, Placebos, Population, Safety, SARS-CoV-2 - immunology, Seroconversion, Severe acute respiratory syndrome coronavirus 2, Spike Glycoprotein, Coronavirus - immunology, Spike protein, United States - epidemiology, Vaccine Efficacy, Vaccines, Young Adult